Pancreatic cancer is a highly malignant disease, with an estimated 5-years survival of 9% [1
]. At diagnosis, approximately 15% of the patients have resectable disease (stage I or II), which indicates surgery followed by systemic therapy [2
]. The CONKO-001 trial is the first randomized controlled trial in pancreatic cancer that reported longer overall survival (OS) rates in patients treated with adjuvant gemcitabine compared with observation alone.
However, the median OS with this regimen is still only 22 months . Recently, Conroy et al. demonstrated a significant survival benefit with modified FOLFIRINOX compared to gemcitabine alone (PRODIGE-24 trial) in highly selected patients . In addition, new chemotherapeutic strategies in combination with gemcitabine are currently explored and also improved the prognosis of pancreatic cancer [4, 5]. Read more . . .